A multi-institutional , randomized , phase II study was undertaken by the National Cancer Institute of Canada-Clinical Trials Group to evaluate the efficacy and toxicity of two doses of oral gefitinib in patients with minimally symptomatic , hormone-refractory prostate cancer ( HRPC ) .
